出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年10月
Continuous Renal Replacement Therapy Market – Global Forecast To 2028
持続的腎代替療法（CRRT）市場 : 製品 (血液フィルター、血液系、機械、透析液)、モダリティ (SCUF、CVVH、CVVHD、CVVHDF)、年齢 (成人、小児)、エンドユーザー (病院、外来)、地域別 – 2028年までの世界予測
Continuous Renal Replacement Therapy Market by Product (Hemofilter, Bloodline, Machines, Dialysates), Modality (SCUF, CVVH, CVVHD, CVVHDF), Age (Adult, Pediatric), Enduser (Hospitals, Ambulatory), and Region – Global Forecast to 2028
| ページ数 | 226 |
| 図表数 | 235 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The global Continuous renal replacement therapy therapy market size is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 8.1% during the forecast period.
Various factors such as increasing incidences of Acute kidney injyury (AKI) and rising prominence on effective renal replacement therapy among patients in ICU and critically ill patients are majorly attributing to the rise in the demand for CRRT system and disposables. Moreover, the technologically advanced CRRT system in the market and rising prevalence of hypertension and rising cases of Acute kidney injury, are some of the factors which are anticipated to drive the demand for Continuous renal replacement therapy therapy during the forecast period.
“The dialysate and replacement fluid segment to capture the largest share in Continuous renal replacement therapy therapy market, by product, during the forecast period.”
The dialysate and replacement fluid segment is expected to witness the high growth rate during the forecast period. The high growth owes to the significant increase in the demand for CRRT in the treatment for the patients who are unstablehemodynamically , the increase in the number of manufacturers who are offering dialysate and replacement fluids for renal replacement therapy, and also the strong presence of players in the market.
“The continuous venovenous hemodiafiltration segment to witness highest growth rate in Continuous renal replacement therapy therapy market, by modality in 2022.”
The continuous venovenous hemodiafiltration modality segment is expected to witness the highest growth rate in the CRRT market during the forecast period. The rising preference of continuous venovenous hemodiafiltrationmodality among nephrologists and critical care physicians, and also the advantages which includes better clearance of medium-sized solutes in comparison to hemodialysis (accurate acid-base balance without intervention, and a significant reduction in CRRT-related phosphate depletion area are some of the factors which supports the growth of the segment in the coming years.
“The Hospital segment accounted for the largest share of the Continuous renal replacement therapy therapy, by age group, in 2022”
The CRRT process mainly adopted in hospitals due to its technological advancements and cost of investment. The economical stability of hospitals among other end users has led to its larger market share. The continuous renal replacement therapy (CRRT) is mostly used treatment in hospitals, especially in the intensive care unit (ICU) or the patients who are critically ill. It can help to stabilize hemodynamic parameters and improve clinical symptoms and organ function in patients, which can help to reduce complications
“The Asia Pacific market to grow at the highest CAGR during the forecast period.”
The Continuous renal replacementtherapy market is segmented into five major regions, , North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The increase in the awareness of Continuous renal replacement therapy therapy, increasing healthcare expenditures, rising of the disposable incomes , rising incidences of sepsis, increasing prevalence of hypertension & diabetes (major causes of AKI), the high use of CRRT in Australia and Japan, , and increasing accessibility to CRRT for AKI treatment are some of the key factors that are playing major role in increase of adoption of the CRRT systems in Asia Pacific region
Breakdown of supply-side primary interviews:
• By Company Type: Tier 1: 25%, Tier 2: 30%, and Tier 3: 45%
• By Designation: C-level: 26%, D-level: 30%, and Others: 44%
• By Region: North America: 40%, Europe: 31%, APAC: 20%, Latin America: 6%, and the Middle East & Africa: 3%
The major players operating in the Continuous renal replacement therapy therapy market are Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International Inc. (US), and B. Braun Melsungen AG (Germany),
Research Coverage
This report studies the Continuous renal replacement therapy therapy market based on the product, modality, age group, end users and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Key Benefits of Buying the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below-mentioned five strategies.
This report provides insights into the following pointers:
• Market Driver: The growth of the market attributes to increase of advanced technology and benefits of using CRRT systems.
• Market Penetration: Comprehensive information on the product portfolios of the top players in the Continuous renal replacement therapy market. The report analyzes the market based on the product, modality, age group, end users and region.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the Continuous renal replacement therapy market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for Continuous renal replacement therapy across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the Continuous renal replacement therapy market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the Continuous renal replacement therapy market
Table of Contents
1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY 31
1.3 MARKET SCOPE 32
1.3.1 MARKETS COVERED 32
FIGURE 1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: REGIONAL SEGMENTATION 32
1.3.2 YEARS CONSIDERED 33
1.4 CURRENCY 33
1.5 MAJOR MARKET STAKEHOLDERS 33
1.6 SUMMARY OF CHANGES 34
1.7 RECESSION IMPACT 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 2 RESEARCH DESIGN 35
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 37
FIGURE 3 PRIMARY SOURCES 38
2.1.2.1 Key data from primary sources 38
2.1.2.2 Insights from industry experts 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 39
FIGURE 5 BREAKDOWN OF PRIMARIES: CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) MARKET 40
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 41
FIGURE 7 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS 41
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: BAXTER INTERNATIONAL INC. 42
FIGURE 9 REVENUE SHARE ANALYSIS FOR TOP PLAYERS 42
FIGURE 10 DEMAND-SIDE MARKET ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 43
FIGURE 11 DEMAND-SIDE MARKET ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY CONSUMABLES 44
FIGURE 12 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET (2023–2028) 45
FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 45
FIGURE 14 TOP-DOWN APPROACH 46
2.3 DATA TRIANGULATION 47
FIGURE 15 DATA TRIANGULATION METHODOLOGY 47
2.4 RESEARCH ASSUMPTIONS 47
2.5 RISK ASSESSMENT 48
TABLE 1 RISK ASSESSMENT: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 48
2.6 LIMITATIONS 48
2.7 METHODOLOGY-RELATED LIMITATIONS 49
2.8 RECESSION IMPACT 49
3 EXECUTIVE SUMMARY 50
FIGURE 16 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 50
FIGURE 17 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2023 VS. 2028 (USD MILLION) 51
FIGURE 18 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2023 VS. 2028 (USD MILLION) 51
FIGURE 19 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 52
FIGURE 20 GEOGRAPHICAL SNAPSHOT OF CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 53
4 PREMIUM INSIGHTS 54
4.1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET OVERVIEW 54
FIGURE 21 RISING PREVALENCE OF ACUTE KIDNEY INJURY AND GROWING AWARENESS OF CRRT TO DRIVE MARKET 54
4.2 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT AND COUNTRY (2022) 55
FIGURE 22 DIALYSATE & REPLACEMENT FLUIDS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022 55
4.3 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 56
FIGURE 23 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 56
4.4 REGIONAL MIX: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET (2021–2028) 57
FIGURE 24 NORTH AMERICA WILL CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD 57
4.5 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: EMERGING VS. DEVELOPED MARKETS 57
FIGURE 25 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 57
5 MARKET OVERVIEW 58
5.1 INTRODUCTION 58
5.2 MARKET DYNAMICS 58
FIGURE 26 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58
5.2.1 DRIVERS 59
5.2.1.1 Increasing incidence of acute kidney injury (AKI) 59
FIGURE 27 GLOBAL INCIDENCE OF ACUTE KIDNEY INJURY, 2010 VS. 2015 VS. 2020 59
TABLE 2 NUMBER OF PEOPLE AGED 65 OR OVER, BY REGION, 2019 VS. 2050 60
5.2.1.2 Growing number of ICU patients with AKI and increasing incidence of sepsis 60
FIGURE 28 IMPACT OF ICU-ACQUIRED AKI IN US 61
5.2.1.3 Increasing clinical advantage of CRRT over intermittent blood purification 61
5.2.1.4 Technological advancements and new product launches 62
5.2.1.5 Growing prevalence of diabetes and hypertension 62
5.2.2 RESTRAINTS 63
5.2.2.1 Stringent regulatory guidelines in North America 63
5.2.2.2 High procedural cost of CRRT 63
5.2.3 OPPORTUNITIES 63
5.2.3.1 Emerging markets in Asia Pacific and RoW 63
5.2.3.2 Increasing applications of CRRT 64
5.2.3.2.1 Evolution of CRRT from simple renal replacement treatment to multi-organ support therapy 64
5.2.3.2.2 Progression of CRRT from adaptive renal devices to multipurpose treatment machines 64
5.2.3.3 Ongoing research to establish safety and efficacy profile of CRRT 64
5.2.3.4 Development of CRRT systems for pediatric patients 65
5.2.3.4.1 The CARPEDIEM Project 65
5.2.3.5 Untapped growth opportunities in North America 65
5.2.4 CHALLENGES 66
5.2.4.1 High complexity of CRRT 66
5.2.4.2 Lack of standard treatment guidelines in developing nations 66
5.2.4.3 Shortage of trained ICU professionals in developing nations 67
5.2.4.4 Poor reimbursement scenario in developing countries 67
5.2.4.5 Lack of awareness about benefits of CRRT 67
5.3 REGULATORY ANALYSIS 68
5.3.1 NORTH AMERICA 68
5.3.2 EUROPE 68
5.3.3 ASIA PACIFIC 68
5.3.3.1 India 68
5.3.3.2 China 68
5.3.3.3 Japan 68
5.3.3.4 South Korea 69
5.3.4 REST OF THE WORLD (ROW) 69
5.3.4.1 Brazil 69
5.3.4.2 Argentina 69
5.4 REIMBURSEMENT SCENARIO 69
5.4.1 NORTH AMERICA 70
5.4.2 EUROPE 70
5.4.3 ASIA PACIFIC 71
5.4.3.1 Japan 71
5.4.4 REST OF THE WORLD (ROW) 71
5.4.4.1 Brazil 71
5.4.4.2 Central America and the Caribbean 71
5.5 KEY CONFERENCES & EVENTS 72
TABLE 3 KEY CONFERENCES & EVENTS, 2023 72
5.6 PATENT ANALYSIS 72
5.6.1 PATENT PUBLICATION TRENDS FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 72
FIGURE 29 PATENT PUBLICATION TRENDS (JANUARY 2013–AUGUST 2023) 73
5.6.2 INSIGHTS ON JURISDICTION AND TOP APPLICANT ANALYSIS 73
FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR CONTINUOUS RENAL REPLACEMENT PATENTS, 2013–2023 74
FIGURE 31 TOP 10 APPLICANT COUNTRIES/REGIONS FOR CONTINUOUS RENAL REPLACEMENT PATENTS, 2013–2023 75
TABLE 4 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: LIST OF MAJOR PATENTS 75
5.7 TRADE ANALYSIS 77
5.8 TECHNOLOGY ANALYSIS 78
5.8.1 MINIMALLY INVASIVE CRRT 78
5.8.2 CRRT IN COMBINATION WITH OTHER THERAPIES 78
5.9 ECOSYSTEM ANALYSIS 78
5.10 VALUE CHAIN ANALYSIS 79
FIGURE 32 VALUE CHAIN OF CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 79
5.11 PRICING TREND ANALYSIS 79
TABLE 5 AVERAGE PRICE OF CRRT SYSTEMS AND CONSUMABLES, BY COUNTRY, 2020 (USD) 80
5.12 PORTER’S FIVE FORCES ANALYSIS 80
TABLE 6 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 80
5.12.1 THREAT OF NEW ENTRANTS 81
5.12.2 THREAT OF SUBSTITUTES 81
5.12.3 BARGAINING POWER OF SUPPLIERS 81
5.12.4 BARGAINING POWER OF BUYERS 81
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 82
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 82
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 82
FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 82
TABLE 7 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 82
5.13.2 BUYING CRITERIA 83
FIGURE 34 KEY BUYING CRITERIA FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 83
TABLE 8 KEY BUYING CRITERIA FOR CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 83
5.14 ARTIFICIAL INTELLIGENCE INTEGRATION IN CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS 83
5.15 UNMET NEED & END-USER EXPECTATIONS WITH CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS 84
6 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT 85
6.1 INTRODUCTION 86
TABLE 9 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 86
6.2 DIALYSATE & REPLACEMENT FLUIDS 86
6.2.1 RISING DEMAND FOR DIALYSATE TO DRIVE MARKET 86
TABLE 10 DIALYSATE & REPLACEMENT FLUIDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
6.3 DISPOSABLES 87
TABLE 11 DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 88
TABLE 12 DISPOSABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
6.3.1 HEMOFILTERS 89
6.3.1.1 Widely adopted during CRRT procedures for treatment of AKI 89
TABLE 13 HEMOFILTERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
6.3.2 BLOODLINE SETS & TUBES 90
6.3.2.1 Development of blood tubing with special coding to prevent clotting to offer growth opportunities 90
TABLE 14 BLOODLINE SETS & TUBES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91
6.3.3 OTHER DISPOSABLES 91
TABLE 15 OTHER DISPOSABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
6.4 CRRT SYSTEMS 92
6.4.1 AVAILABILITY OF TECHNOLOGICALLY ADVANCED, EASY-TO-USE SYSTEMS TO BOOST MARKET GROWTH 92
TABLE 16 CRRT SYSTEMS MARKET BY COUNTRY, 2021–2028 (USD MILLION) 93
7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY 94
7.1 INTRODUCTION 95
TABLE 17 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 95
7.2 CONTINUOUS VENOVENOUS HEMOFILTRATION 95
7.2.1 WIDESPREAD ADOPTION IN TREATMENT OF ACUTE KIDNEY INJURY TO DRIVE MARKET 95
TABLE 18 CONTINUOUS VENOVENOUS HEMOFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
7.3 CONTINUOUS VENOVENOUS HEMODIAFILTRATION 97
7.3.1 USED IN PATIENTS WITH CONGESTIVE HEART FAILURE 97
TABLE 19 CONTINUOUS VENOVENOUS HEMODIAFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
7.4 CONTINUOUS VENOVENOUS HEMODIALYSIS 98
7.4.1 MORE EFFECTIVE IN REMOVING SMALL TO MEDIUM-SIZED MOLECULES COMPARED TO OTHER CRRT MODALITIES 98
TABLE 20 CONTINUOUS VENOVENOUS HEMODIALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
7.5 SLOW CONTINUOUS ULTRAFILTRATION 99
7.5.1 DOES NOT USE DIALYSATE OR REPLACEMENT FLUIDS FOR REMOVAL OF EXCESS FLUID FROM BLOODSTREAM 99
TABLE 21 SLOW CONTINUOUS ULTRAFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
8 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP 101
8.1 INTRODUCTION 102
TABLE 22 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 102
8.2 ADULTS 102
8.2.1 LARGEST AND FASTEST-GROWING SEGMENT OF MARKET 102
TABLE 23 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR ADULTS, BY COUNTRY, 2021–2028 (USD MILLION) 103
8.3 PEDIATRICS & NEONATES 103
8.3.1 HIGH PREVALENCE OF AKI IN NEONATES TO SUPPORT MARKET GROWTH 103
TABLE 24 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR PEDIATRICS & NEONATES, BY COUNTRY, 2021–2028 (USD MILLION) 104
9 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER 105
9.1 INTRODUCTION 106
TABLE 25 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 106
9.2 HOSPITALS 106
9.2.1 FASTEST-GROWING END-USER SEGMENT 106
TABLE 26 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION) 107
9.3 AMBULATORY CARE 107
9.3.1 REDUCED INPATIENT STAY TO SUPPORT MARKET GROWTH 107
TABLE 27 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR AMBULATORY CARE, BY COUNTRY, 2021–2028 (USD MILLION) 108
9.4 HOME CARE 108
9.4.1 RISING ADOPTION OF PORTABLE AND HOME-BASED DEVICES TO AID MARKET GROWTH 108
TABLE 28 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR HOME CARE, BY COUNTRY, 2021–2028 (USD MILLION) 109
9.5 OTHER END USERS 109
TABLE 29 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 110
10 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION 111
10.1 INTRODUCTION 112
TABLE 30 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 112
10.2 NORTH AMERICA 113
10.2.1 NORTH AMERICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT 113
FIGURE 35 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SNAPSHOT 114
TABLE 31 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 32 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 115
TABLE 33 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 34 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 116
TABLE 35 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 116
TABLE 36 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 116
10.2.2 US 117
10.2.2.1 Large number of AKI patients to drive market 117
TABLE 37 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 118
TABLE 38 US: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 39 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 118
TABLE 40 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 119
TABLE 41 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 119
10.2.3 CANADA 119
10.2.3.1 High cost of CRRT to negatively impact market growth 119
TABLE 42 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 120
TABLE 43 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 44 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 121
TABLE 45 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 121
TABLE 46 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 121
10.3 EUROPE 122
10.3.1 EUROPEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT 122
TABLE 47 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 48 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 123
TABLE 49 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 50 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 124
TABLE 51 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 124
TABLE 52 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 124
10.3.2 GERMANY 125
10.3.2.1 Largest market for continuous renal replacement therapy in Europe 125
TABLE 53 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125
TABLE 54 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 55 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 126
TABLE 56 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 126
TABLE 57 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 126
10.3.3 UK 127
10.3.3.1 Rising number of sepsis cases to support market growth 127
TABLE 58 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 127
TABLE 59 UK: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 60 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 128
TABLE 61 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 128
TABLE 62 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 129
10.3.4 FRANCE 129
10.3.4.1 Growing AKI patient population to propel market growth 129
TABLE 63 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 129
TABLE 64 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 65 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 130
TABLE 66 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 130
TABLE 67 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 131
10.3.5 ITALY 131
10.3.5.1 Government initiatives to promote awareness of renal care to drive market 131
TABLE 68 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 132
TABLE 69 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 70 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 132
TABLE 71 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 133
TABLE 72 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 133
10.3.6 SPAIN 133
10.3.6.1 Favorable reimbursement scenario to favor market growth 133
TABLE 73 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 134
TABLE 74 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 75 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 134
TABLE 76 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 135
TABLE 77 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 135
10.3.7 REST OF EUROPE 135
TABLE 78 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 136
TABLE 79 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
TABLE 80 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 136
TABLE 81 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 137
TABLE 82 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 137
10.4 ASIA PACIFIC 137
10.4.1 ASIA PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT 138
FIGURE 36 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SNAPSHOT 138
TABLE 83 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 84 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 139
TABLE 85 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 86 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 140
TABLE 87 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 140
TABLE 88 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 140
10.4.2 JAPAN 141
10.4.2.1 Well-established medical infrastructure to support market growth 141
TABLE 89 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 141
TABLE 90 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 91 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 142
TABLE 92 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 142
TABLE 93 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 143
10.4.3 CHINA 143
10.4.3.1 Increasing prevalence of ESRD and AKI to boost demand for CRRT 143
TABLE 94 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 144
TABLE 95 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 96 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 144
TABLE 97 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 145
TABLE 98 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 145
10.4.4 INDIA 145
10.4.4.1 Large patient population to support market growth 145
TABLE 99 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 146
TABLE 100 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 101 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 147
TABLE 102 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 147
TABLE 103 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 147
10.4.5 AUSTRALIA 148
10.4.5.1 Government initiatives to increase adoption of CRRT 148
TABLE 104 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 148
TABLE 105 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 106 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 149
TABLE 107 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 149
TABLE 108 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 149
10.4.6 SOUTH KOREA 150
10.4.6.1 Increasing awareness through online education programs and events to aid market growth 150
TABLE 109 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 150
TABLE 110 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 111 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 151
TABLE 112 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 151
TABLE 113 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 152
10.4.7 REST OF ASIA PACIFIC 152
TABLE 114 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 152
TABLE 115 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 116 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 153
TABLE 117 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 153
TABLE 118 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 154
10.5 LATIN AMERICA 154
10.5.1 LATIN AMERICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT 154
TABLE 119 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 120 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 155
TABLE 121 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 122 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 156
TABLE 123 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 156
TABLE 124 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 156
10.5.2 BRAZIL 157
10.5.2.1 Rising incidence of AKI to drive market 157
TABLE 125 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 157
TABLE 126 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 127 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 158
TABLE 128 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 158
TABLE 129 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 158
10.5.3 MEXICO 159
10.5.3.1 Large patient population to drive market 159
TABLE 130 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 159
TABLE 131 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 132 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 160
TABLE 133 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 160
TABLE 134 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 160
10.5.4 REST OF LATIN AMERICA 161
TABLE 135 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 161
TABLE 136 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 137 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 162
TABLE 138 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 162
TABLE 139 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 162
10.6 MIDDLE EAST & AFRICA 163
10.6.1 LACK OF AWARENESS REGARDING CRRT TO RESTRAIN MARKET GROWTH 163
10.6.2 MIDDLE EAST AND AFRICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT 163
TABLE 140 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 163
TABLE 141 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 142 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021–2028 (USD MILLION) 164
TABLE 143 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021–2028 (USD MILLION) 164
TABLE 144 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER, 2021–2028 (USD MILLION) 165
11 COMPETITIVE LANDSCAPE 166
11.1 OVERVIEW 166
FIGURE 37 GROWTH STRATEGIES ADOPTED BY KEY PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 166
11.2 REVENUE SHARE ANALYSIS OF MARKET PLAYERS, 2018–2022 (USD MILLION) 167
FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 167
FIGURE 39 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022 167
TABLE 145 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DEGREE OF COMPETITION 168
11.3 COMPANY EVALUATION MATRIX 169
11.3.1 STARS 169
11.3.2 EMERGING LEADERS 169
11.3.3 PERVASIVE PLAYERS 169
11.3.4 PARTICIPANTS 169
FIGURE 40 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: COMPANY EVALUATION MATRIX, 2022 170
11.4 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 170
11.4.1 PROGRESSIVE COMPANIES 171
11.4.2 STARTING BLOCKS 171
11.4.3 RESPONSIVE COMPANIES 171
11.4.4 DYNAMIC COMPANIES 171
FIGURE 41 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022 172
11.5 FOOTPRINT ANALYSIS OF PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 173
TABLE 146 PRODUCT, REGIONAL, AND END-USER FOOTPRINT ANALYSIS OF PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 173
TABLE 147 PRODUCT FOOTPRINT OF COMPANIES 174
TABLE 148 END-USER FOOTPRINT OF COMPANIES 175
TABLE 149 REGIONAL FOOTPRINT OF COMPANIES 176
11.6 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: PRODUCT LAUNCHES AND REGULATORY APPROVALS (JANUARY 2019 TO AUGUST 2023) 177
TABLE 150 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS 177
11.7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DEALS (JANUARY 2019 TO AUGUST 2023) 178
TABLE 151 KEY DEALS 178
11.8 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: OTHER DEVELOPMENTS (JANUARY 2019 TO AUGUST 2023) 179
TABLE 152 OTHER KEY DEVELOPMENTS 179
12 COMPANY PROFILES 180
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1 MAJOR PLAYERS 180
12.1.1 BAXTER INTERNATIONAL, INC. 180
TABLE 153 BAXTER INTERNATIONAL, INC.: BUSINESS OVERVIEW 180
FIGURE 42 BAXTER INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022) 181
TABLE 154 BAXTER INTERNATIONAL, INC.: PRODUCT OFFERINGS 181
12.1.2 FRESENIUS MEDICAL CARE AG & CO. KGAA 185
TABLE 155 FRESENIUS MEDICAL CARE AG & CO. KGAA: BUSINESS OVERVIEW 185
FIGURE 43 FRESENIUS MEDICAL CARE AG & CO. KGAA: COMPANY SNAPSHOT (2022) 186
TABLE 156 FRESENIUS MEDICAL CARE AG & CO. KGAA: PRODUCT OFFERINGS 186
12.1.3 NIKKISO CO., LTD. 189
TABLE 157 NIKKISO CO., LTD.: BUSINESS OVERVIEW 189
FIGURE 44 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022) 190
TABLE 158 NIKKISO CO., LTD.: PRODUCT OFFERINGS 190
12.1.4 B. BRAUN MELSUNGEN AG 192
TABLE 159 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW 192
FIGURE 45 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2022) 193
TABLE 160 B. BRAUN MELSUNGEN AG: PRODUCT OFFERINGS 193
12.1.5 MEDTRONIC PLC 196
TABLE 161 MEDTRONIC PLC: BUSINESS OVERVIEW 196
FIGURE 46 MEDTRONIC PLC: COMPANY SNAPSHOT (2022) 197
TABLE 162 MEDTRONIC PLC: PRODUCT OFFERINGS 197
12.1.6 ASAHI KASEI CORPORATION 200
TABLE 163 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW 200
FIGURE 47 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022) 201
TABLE 164 ASAHI KASEI CORPORATION: PRODUCT OFFERINGS 201
12.1.7 TORAY MEDICAL CO., LTD. 203
TABLE 165 TORAY MEDICAL CO., LTD.: BUSINESS OVERVIEW 203
FIGURE 48 TORAY MEDICAL CO., LTD.: COMPANY SNAPSHOT (2022) 204
TABLE 166 TORAY MEDICAL CO., LTD.: PRODUCT OFFERINGS 204
12.1.8 NIPRO CORPORATION 206
TABLE 167 NIPRO CORPORATION: BUSINESS OVERVIEW 206
FIGURE 49 NIPRO CORPORATION: COMPANY SNAPSHOT (2022) 206
TABLE 168 NIPRO CORPORATION: PRODUCT OFFERINGS 207
12.1.9 INFOMED SA 209
TABLE 169 INFOMED SA: BUSINESS OVERVIEW 209
TABLE 170 INFOMED SA: PRODUCT OFFERINGS 209
12.1.10 MEDICA SPA 210
TABLE 171 MEDICA SPA: BUSINESS OVERVIEW 210
TABLE 172 MEDICA SPA: PRODUCT OFFERINGS 210
12.1.11 MEDITES PHARMA SPOL. S.R.O. 212
TABLE 173 MEDITES PHARMA SPOL. S.R.O.: BUSINESS OVERVIEW 212
TABLE 174 MEDITES PHARMA SPOL. S.R.O.: PRODUCT OFFERINGS 212
12.1.12 MEDICAL COMPONENTS, INC. 213
TABLE 175 MEDICAL COMPONENTS, INC.: BUSINESS OVERVIEW 213
TABLE 176 MEDICAL COMPONENTS, INC.: PRODUCT OFFERINGS 213
12.1.13 SWS HEMODIALYSIS CARE CO., LTD. 215
TABLE 177 SWS HEMODIALYSIS CARE CO., LTD.: BUSINESS OVERVIEW 215
TABLE 178 SWS HEMODIALYSIS CARE CO., LTD.: PRODUCT OFFERINGS 215
12.1.14 NINGBO TIANYI MEDICAL DEVICES CO., LTD. 217
TABLE 179 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: BUSINESS OVERVIEW 217
TABLE 180 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: PRODUCT OFFERINGS 217
12.1.15 ANJUE MEDICAL EQUIPMENT CO., LTD. 218
TABLE 181 ANJUE MEDICAL EQUIPMENT CO., LTD.: BUSINESS OVERVIEW 218
TABLE 182 ANJUE MEDICAL EQUIPMENT CO., LTD.: PRODUCT OFFERINGS 218
12.1.16 KIMAL 220
TABLE 183 KIMAL: BUSINESS OVERVIEW 220
TABLE 184 KIMAL.: PRODUCT OFFERINGS 220
12.1.17 JIANGXI SANXIN MEDTEC CO., LTD. 221
TABLE 185 JIANGXI SANXIAN MEDTECH CO., LTD.: BUSINESS OVERVIEW 221
TABLE 186 JIANGXI SANXIAN MEDTECH CO., LTD.: PRODUCT OFFERINGS 221
12.2 OTHER PLAYERS 222
12.2.1 ALLMED MEDICAL PRODUCTS CO., LTD. 222
12.2.2 DIALCO MEDICAL INC. 222
12.2.3 BROWNDOVE HEALTHCARE PVT. LTD. 223
12.2.4 STERIS PLC 223
12.2.5 KURARAY MEDICAL PLC 224
12.2.6 LIVANOVA PLC 224
12.2.7 DIAVERUM DEUTSCHLAND GMBH 225
12.2.8 SEMBCORP INDUSTRIES 225
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 226
13.1 DISCUSSION GUIDE 226
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 230
13.3 CUSTOMIZATION OPTIONS 232
13.4 RELATED REPORTS 232
13.5 AUTHOR DETAILS 233